Chloroform

Chloroform

SCHEMBL98767

CC(C)OC(C)C.ClC(Cl)Cl

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
TSHR P16473 1/20 0.42
LMNA P02545 1/20 0.36
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloroform SCHEMBL4322061 0.92 ALDH1A1 (0.36) ALDH1A1TSHRLMNAMAPK1
SCHEMBL6520578 0.91 ALDH1A1 (0.55) ALDH1A1TSHRMAPK1
Isopropyl Alcohol SCHEMBL9024795 0.89 ALDH1A1 (0.43) ALDH1A1TSHRLMNA
Chloromethane SCHEMBL11103401 0.86
SCHEMBL10940023 0.85
SCHEMBL7240952 0.85
SCHEMBL1296 0.85
SCHEMBL1331944 0.85
Chloroform SCHEMBL7162033 0.83 TSHR (0.38) ALDH1A1TSHRMAPK1
Acetic Acid SCHEMBL8834833 0.80 FFAR3 (0.41) ALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102603797-A Phosphine imide ligand (E)-(2-(diphenyl phosphino) benzylidene) hydrazine as well as synthetic method and application of phosphine imide ligand (E)-(2-(diphenyl phosphino) benzylidene) hydrazine UNIV NANKAI 2012-07-25 CN claimed
EP-0225130-B1 LIPOSOME COMPOSITION Takeda Chemical Industries, Ltd. (JP) 1991-10-30 EP claimed
US-4844904-A Liposome composition TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1989-07-04 US claimed
CN-116375734-A Ballon Sha Weizhi isomer and preparation method thereof 思科(深圳)药物研发有限公司 2023-07-04 CN disclosed
CN-106232587-B Disubstituted 1,2, 4-triazine compounds 田边三菱制药株式会社 2021-04-13 CN disclosed
US-20210093640-A1 Polycyclic Carbamoylpyridone Derivatives, Pharmaceutical Compositions and Use Thereof ANDIKANG (WUXI) BIOLOGICAL TECHNOLOGY CO. LTD. (CN) 2021-04-01 US disclosed
EP-3778608-A1 POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF Andikang (Wuxi) Biological Technology Co., Ltd. (CN) 2021-02-17 EP disclosed
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) 2019-09-12 US disclosed
US-10329263-B2 Disubstituted 1, 2, 4-triazine compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-06-25 US disclosed
EP-3473616-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF Wakunaga Pharmaceutical Co., Ltd. (JP) 2019-04-24 EP disclosed
CN-107099347-B A kind of ether diesel oil of clean and environmental protection and preparation method thereof 孟宪富 2019-03-29 CN disclosed
US-4336368-A 4 Deoxy-4-methylene oleandomycin and derivatives thereof PFIZER INC. (US) 1982-06-22 US disclosed
EP-0051381-A1 O-sulfated beta-lactam hydroxamic acids E.R. Squibb & Sons, Inc. (US) 1982-05-12 EP disclosed
US-4283340-A VITAMINS PFIZER INC. (US) 1981-08-11 US disclosed
EP-0000243-B1 PROCESS FOR PREPARING 3,5:4,6- PROTECTED DERIVATIVES OF L- OR D- GULONIC ACID, THEIR USE IN PREPARING 2- KETO-L- OR D- GULONIC ACID OR THEIR ESTERS OR L- OR D- ASCORBIC ACID, AND CERTAIN NOVEL 2-NITRATO-GULONATE INTERMEDIATES PFIZER INC. (US) 1981-01-07 EP disclosed
US-4228167-A Diuretic and vasodilating tricyclic quinazolines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-10-14 US disclosed
EP-0000243-A1 Process for preparing 3,5:4,6- protected derivatives of L- or D- gulonic acid, their use in preparing 2- keto-L- or D- gulonic acid or their esters or L- or D- ascorbic acid, and certain novel 2-nitrato-gulonate intermediates PFIZER INC. (US) 1979-01-10 EP disclosed
US-4052436-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1977-10-04 US disclosed
US-4051129-A REACTION OF BENZYLIDENIMINO GROUP WITH HYDRAZINE, AMIDATION SANKYO COMPANY LIMITED (JA) 1977-09-27 US disclosed
US-3989841-A ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329263-B2 Disubstituted 1, 2, 4-triazine compound NR3C2, REN, NR5A1 ALDH1A1 68/4885TSHR 759/4885LMNA 2988/4885
US-20190276407-A1 NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF CTR9, PYCR1, ACAD9 ALDH1A1 960/4885TSHR 234/4885LMNA 1870/4885
US-20210093640-A1 Polycyclic Carbamoylpyridone Derivatives, Pharmaceutical Compositions and Use Thereof RNGTT, HDAC5, ENTPD5 ALDH1A1 1462/4885TSHR 4238/4885LMNA 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.